Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBITDA: 2016-2024

Historic EBITDA for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to -$1.3 million.

  • Organogenesis Holdings' EBITDA rose 232.06% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of -$1.3 million for FY2024, which is 110.24% down from last year.
  • Latest data reveals that Organogenesis Holdings reported EBITDA of -$1.3 million as of FY2024, which was down 110.24% from $12.5 million recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' EBITDA ranged from a high of $72.2 million in FY2021 and a low of -$1.3 million during FY2024.
  • In the last 3 years, Organogenesis Holdings' EBITDA had a median value of $12.5 million in 2023 and averaged $11.2 million.
  • Per our database at Business Quant, Organogenesis Holdings' EBITDA spiked by 189.44% in 2020 and then slumped by 110.24% in 2024.
  • Organogenesis Holdings' EBITDA (Yearly) stood at $26.7 million in 2020, then soared by 170.48% to $72.2 million in 2021, then tumbled by 69.12% to $22.3 million in 2022, then slumped by 43.84% to $12.5 million in 2023, then tumbled by 110.24% to -$1.3 million in 2024.